{"id":10195,"date":"2024-05-28T02:21:49","date_gmt":"2024-05-28T02:21:49","guid":{"rendered":"https:\/\/economicherald.net\/?p=10195"},"modified":"2024-05-28T02:21:49","modified_gmt":"2024-05-28T02:21:49","slug":"asx-health-stocks-painchek-wins-european-patent-phase-3-trial-set-to-begin-for-opthea","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=10195","title":{"rendered":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea"},"content":{"rendered":"<p>PainChek granted patent in Europe<\/p>\n<p><a href=\"https:\/\/stockhead.com.au\/company\/painchek-pck\/\">PainChek (ASX:PCK)<\/a> has been granted a patent in 20 European nations by the European Patent Office (EPO).<\/p>\n<p>The patent was given for the PainChek app, an AI platform designed to analyse facial expressions, vocalisations, movements, and body language to assess the presence and intensity of pain.<\/p>\n<p>The patent, called <em>\u201cA Pain Assessment Method and System\u201d,<\/em> gives PainChek legal protection for the tech in European countries like Austria, Belgium, Germany, and the UK \u2013 and it\u2019s good until 2035.<\/p>\n<p>This patent also adds more muscle to PainChek\u2019s worldwide collection of intellectual property.\u00a0This portfolio is already pretty impressive, with patents in major markets like the USA, Japan, and China.<\/p>\n<p><em>Philip Dafas, CEO of PainChek,<\/em> commented:<\/p>\n<p>\u201cThe granting of this European patent is a pivotal achievement for PainChek as it solidifies our position in one of the world\u2019s largest healthcare markets, including the UK which is a particularly important growth region for the company.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Opthea set to commence Phase 3 trial<\/h2>\n<p>Opthea says it has just finished enrolling patients in both the <strong>COAST<\/strong> and <strong>ShORe<\/strong> trials, which are part of its pivotal Phase 3 clinical program.<\/p>\n<p>This program is testing a treatment called <strong>sozinibercept<\/strong> alongside the usual anti-VEGF-A therapies for wet age-related macular degeneration (wet AMD).<\/p>\n<p>The aim is to see if this combo treatment is safer and more effective than the standard treatment alone.<\/p>\n<p>The two trials, COAST and ShORe, will involve nearly 2,000 patients who are new to treatment for wet age-related macular degeneration (wet AMD), making this one of the largest Phase 3 programs for this condition.<\/p>\n<p>The primary endpoint for both trials is the mean change in <em>Best Corrected Visual Acuity (BCVA)<\/em> from baseline to week 52. Both trials are also evaluating the safety and tolerability over a two-year period.<\/p>\n<p><em>Opthea\u2019s CEO, Frederic Guerard<\/em>, commented:<\/p>\n<p>\u201cSozinibercept is the only late-stage asset in development in over 15 years that is targeting better visual outcomes for wet AMD patients in combination with standard-of- care anti-VEGF-A therapies.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Pro Medicus nabs US deals worth at least $45m<\/h2>\n<p>Meanwhile, heavyweight health imaging company, <strong><a href=\"https:\/\/stockhead.com.au\/company\/promedicus-pme\/\">Pro Medicus (ASX:PME)<\/a><\/strong>, said its subsidiary, <em>Visage Imaging,<\/em> has secured five new contracts in the US totalling a minimum of $45m.<\/p>\n<p>These contracts are all for Cloud deployment, and are expected to be completed within the next six months.<\/p>\n<p>Some of the deals include: a $9.5m contract with Consulting Radiology, a private radiology group in Minnesota, spanning five years; and a $11.5m contract for seven years with Nationwide Children\u2019s Hospital, a renowned paediatric hospital in Columbus, Ohio.<\/p>\n<p>These new contracts significantly boost Pro Medicus\u2019 total contract value for new sales this financial year to $245 million.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-painchek-wins-european-patent-phase-3-trial-set-to-begin-for-opthea\/\">ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was <a href=\"https:\/\/economicherald.net\/?p=10195\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":10196,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-10195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=10195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=10195\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-28T02:21:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea\",\"datePublished\":\"2024-05-28T02:21:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195\"},\"wordCount\":475,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=10195\",\"name\":\"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg\",\"datePublished\":\"2024-05-28T02:21:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=10195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=10195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=10195","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald","og_description":"PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was [more...]","og_url":"https:\/\/economicherald.net\/?p=10195","og_site_name":"Economic Herald","article_published_time":"2024-05-28T02:21:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=10195#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=10195"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea","datePublished":"2024-05-28T02:21:49+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=10195"},"wordCount":475,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=10195#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=10195","url":"https:\/\/economicherald.net\/?p=10195","name":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=10195#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=10195#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg","datePublished":"2024-05-28T02:21:49+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=10195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=10195"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=10195#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/PainChek-wins-European-patent-and-Phase-3-Trial-set-to-begin-for-Opthea.-Picture-Getty-YhUNVR.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=10195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: PainChek wins European patent; Phase 3 Trial set to begin for Opthea"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/10195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10195"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/10195\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/10196"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}